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Polyomavirus-associated nephropathy (PVAN) is a frequent
cause of kidney transplant failure. We determined the risk
factors for biopsy-proven PVAN among 1027 recent kidney
transplant recipients by univariate and multivariate analyses.
The rate of PVAN was determined over an univariate and
multivariate analysis over an average of 30 months of
follow-up of patients receiving predominantly living donor
grafts with antibody induction and sequential surveillance
biopsies to detect subclinical graft disease. Seventy-four
transplant recipients were diagnosed with PVAN with the
finding made on surveillance biopsy in 40 patients. These 40
cases did not differ from the 34 non-surveillance cases with
respect to baseline clinical characteristics or initial
histological features. Older recipient age and female donor
gender were independent risks associated with PVAN.
Factors not linked to PVAN risk included the use and type of
induction agent, use of tacrolimus vs sirolimus, the number
of human lympocyte antigen (HLA) mismatches, or the
frequency of acute rejection. We conclude that PVAN
preferentially affects older age patients and allografts from
female donors but is unrelated to immunological risk, choice
of immunosuppression, or rejection history.
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Polyomavirus-associated nephropathy (PVAN) owing to BK
virus (BKV) is now a frequent cause of kidney transplant
(KTx) injury and failure worldwide.1–4 Although BKV was
recognized as a commonly reactivated virus within the
uroepithelium of immunosuppressed individuals over 30
years ago,5,6 the emergence of PVAN as a clinicopathological
entity in 2% to 10% of KTx recipients has occurred only
within the past 8 years.1–4,7–12 The primary reason for this
apparent shift in the pathogenicity of BKV reactivation is
generally accepted to be the introduction of highly potent
immunosuppressive drug combinations into clinical practice
during the same time period.1–4 Despite this assumption,
however, current evidence does not favor a specific role for
induction therapy or for individual oral immunosuppres-
sants in enhancing PVAN risk.1,8,10–14 Furthermore, careful
analysis of KTx populations managed no differently to those
from the so-called ‘cyclosporine era’ reveals BK viremia, and
PVAN rates similar to those managed by more recently
adopted regimens.10,14 In addition, while some centers have
observed a relationship between immunosuppression boosts
for acute rejection and subsequent development of PVAN,1,9
this practice has clearly become less prevalent with the
decline in acute rejection rates and should not be responsible
for increased incidence of PVAN. Thus, it is worth
considering the possibility that additional factors may be at
play in the dramatic increase in PVAN and that identification
of such factors may contribute, not just to a reduction in the
burden of BKV-associated disease, but also to effective
tailoring of antirejection therapy to minimize the conse-
quences of overimmunosuppression among vulnerable KTx
recipients in the current era.
In common with many other centers, our KTx program
experienced a surge in PVAN cases between 2000 and 2004
that coincided with the use of immunosuppressive regimens
designed to achieve very low acute rejection rates.15 During
that same time period, our practice was also characterized by
increases in overall transplant numbers, living donation rates,
recipient age, and immunological complexity as well as by the
adoption of a surveillance (‘protocol’) biopsy program that
has facilitated diagnosis of subclinical graft disease.12,15–17 In
this study, we have had the opportunity to examine the
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association between biopsy-proven PVAN and an array of
potential risk factors among our entire cohort of recently
transplanted patients. The results of this analysis indicate
that, for the type of practice we have chosen to adopt, PVAN
has preferentially affected recipients of older age and also
allografts from female donors. In contrast, indices reflecting
choice of immunosuppressive agent, recipient immunologi-
cal risk, and actual immunologic complications were not
clearly associated with heightened PVAN risk. Taken in the
context of existing literature, the findings highlight the fact
that PVAN risk factors differ among transplant centers in a
manner that appears to reflect donor/recipient characteristics
as well allocation and immunosuppression practices.
RESULTS
Trends in biopsy-proven PVAN among total KTx recipients
The characteristics of the overall study population are
displayed in Table 1. During a mean follow-up period of
30717 months, 97 KTx recipients died (9%) and an
additional 103 (10%) suffered allograft loss. A total of 74
patients received a biopsy diagnosis of PVAN (7%) at a mean
of 12711 months post-transplant (range 2–63). To date, the
proportions of patients transplanted in 2000, 2001, 2002,
2003, and 2004 that have developed biopsy-proven PVAN are
8%, 10.5%, 7%, 4%, and 5% respectively. Fifty-four percent
of the cases (40) were diagnosed by surveillance biopsy at 4
months (27%), 12 months (23%), 24 months (2.7%), or 60
months (1.3%) post-transplant with the remaining 34 cases
(46%) diagnosed on biopsies performed to investigate raised
serum creatinine (non-surveillance biopsy). As illustrated in
Figure 1a, surveillance biopsy-diagnosed and non-surveil-
lance biopsy-diagnosed cases of PVAN were predominantly
diagnosed within the first 2 years post-KTx. The average time
from transplantation to diagnosis of PVAN was lower in
those diagnosed by surveillance biopsy (10710 months)
compared with those diagnosed by non-surveillance biopsy
(14711 months) but not significantly so (P¼ 0.09). The
incidence of PVAN did not differ among KTx recipients
managed with Thymoglobulin compared with anti-IL-2
receptor antibody induction (Figure 1b). Although there
was a trend toward higher incidence among recipients
managed with tacrolimus- compared with sirolimus- or
cyclosporine-based immunosuppression (Figure 1c), this did
not reach statistical significance.
Clinical characteristics of KTx recipients with and without
PVAN
The clinical characteristics of KTx recipients with and without
biopsy-proven PVAN are summarized in Table 2. As can be
seen, compared to patients without PVAN, those diagnosed
with PVAN were significantly older at the time of transplanta-
tion and were more likely to receive a transplant from a female
donor, whereas there were no significant differences between
the two groups for donor source, donor age, total HLA
mismatches, frequency of acute rejection before the diagnosis
of PVAN. Table 2 also indicates that the groups were closely
comparable with regard to the use and/or type of induction
therapy as well as for the proportionate use of tacrolimus,
sirolimus and cyclosporine. In addition, there were no
significant differences between the two groups for frequency
of preemptive transplantation or re-transplantation, for type
of transplant (conventional vs ABO incompatible/positive
cross-match), for race of either the donor or recipient, or for
occurrence of delayed graft function (data not shown).
The clinical characteristics of patients diagnosed with
PVAN by surveillance biopsy were compared with those
diagnosed by non-surveillance biopsy. None of the charac-
teristics listed in Table 2 differed significantly between these
two groups of patients (data not shown). The surveillance
biopsy and non-surveillance biopsy-diagnosed cases were also
compared for acute and chronic tubulointerstitial abnorm-
alities of the diagnostic allograft biopsy using relevant Banff
’97 scores (iþ t for acute infiltrates and tubulitis, ciþ ct for
interstitial fibrosis and tubular atrophy) and the PVAN
grading system devised by Drachenberg et al.1 (A, B, and C
grades). As shown in Figure 2a, the proportion of cases with
no, mild, moderate, and severe acute abnormalities were not
different between the two groups (P¼ 0.3). A trend toward
more frequent occurrence of moderate or severe chronic
abnormalities among the non-surveillance biopsy-diagnosed
cases was present but did not reach statistical significance
(P¼ 0.15). The distribution of Drachenberg grades did not
differ between the two groups (P¼ 0.7) with the large
majority of each meeting criteria for grade B disease (Figure
2b). In contrast to baseline clinical and histological features,
graft survival during the first 4 years of post-KTx was clearly
superior for PVAN cases diagnosed by surveillance compared
with non-surveillance biopsy (Figure 3). In keeping with
our previous findings,15 we interpreted these analyses as
indicating that PVAN diagnosed by surveillance biopsy, while
associated with improved disease outcome, does not
Table 1 | Baseline characteristics of patients receiving kidney
transplants between January 2000 and June 2004
Number 1027
Donor source, n (%)
Living related 524 (51)
Living unrelated 298 (29)
Deceased 205 (20)
Type of transplant, n (%)
Conventional 900 (85)
ABO incompatible 50 (6)
Positive cross-match 77 (8)
Recipient age (years), mean7s.d. 50714
Recipient gender, % female 43
Recipient race, % Caucasian 90
Pretransplant diabetes mellitus, % 33
Pretransplant dialysis, % 60
Donor age (years), mean7s.d. 41713
Donor gender, % female 52
Total HLA mismatches, mean7s.d. 2.971.7
First transplant, % 78
HLA, human lympocyte antigen.
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represent a distinctly different group with regard to clinical
characteristics or histological features. Hence, further uni-
variate and multivariate risk factor analyses were performed
for the entire cohort of 74 biopsy-proven cases.
Recipient age and donor gender as risk factors for PVAN
The relationships between PVAN diagnosis during follow-up
and recipient age and donor gender were demonstrable by
univariate Cox regression analysis (Table 3). In contrast, the
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Figure 1 | The incidence of PVAN among recent KTx recipients. Kaplan–Meier curves are shown for (a). The cumulative occurrence of
biopsy-proven PVAN among all 1027 patients receiving KTxs at Mayo Clinic between January 2000 and September 2004 and followed for up to
48 months post-transplantation. Cumulative occurrence of cases diagnosed by surveillance biopsy and non-surveillance biopsy is also shown.
(b) KTx recipients managed with thymoglobulin compared with anti-IL2 receptor antibody (anti-CD25). (c). KTx recipients managed with
tacrolimus, sirolimus, or cyclosporine as primary oral immunosuppressive agent. For (b) and (c) the number of KTx recipients in each subgroup
at 0 months post-transplant is shown. There were no statistically significant differences for PVAN incidence among the subgroups analyzed.
Table 2 | Clinical characteristics of kidney transplant recipients without and with biopsy-proven PVAN during follow-up
No PVAN (n=953) PVAN (n=74) P-value
Donor source (%) NSa
Living related 51% 55%
Living unrelated 29% 24%
Deceased 20% 21%
Recipient age (years), mean7s.d. 50715 55713 o0.001b
Recipient older than 55 years, % 45% 62% 0.007a
Recipient gender, % female 44% 35% NSa
Diabetes mellitus (pre- or post-KTx), % 67% 68% NSa
Diabetes mellitus (post-KTx only)c, % 22% 29% NSa
Donor age (years), mean7s.d. 41713 44712 NSb
Donor gender, % female 51% 66% 0.01a
Total HLA mismatches, mean7s.d. 2.971.7 3.071.7 NSd
Acute rejection, %e 18% 15% NSa
Induction (none/ATG/anti-IL2R), % 7%/83%/10% 7%/80%/13% NSa
Oral mmunosuppression (TAC/SRL/CYA), % 87%, 11%, 2% 92%, 7%, 1% NSa
CYA, cyclosporine; HLA, human lympocyte antigen; SRL, sirolimus; TAC, tacrolimus.
aw2.
bStudent t-test.
cDefined according to American Diabetes Association diagnostic criteria.
dNon-parametric t-test (Mann–Whitney).
eFor PVAN cases the analysis includes biopsy-proven clinical, subclinical and borderline acute rejection episodes that occurred prior to the diagnosis of PVAN and were
treated with corticosteroid with or without depleting antibody.
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following variables did not relate significantly with PVAN:
the occurrence of acute rejection episodes before the
diagnosis of PVAN; the use and type of induction agent;
the type of maintenance immunosuppressive regimen
(all shown on Table 3); the type of donor (living or
deceased); the recipient sex or race; the recipient history of
diabetes and/or dialysis pretransplant; the type of transplant
(conventional vs ABO incompatible vs positive cross-match);
the occurrence of delayed graft function; number of HLA
mismatches; or the graft function at 3 weeks after
transplantation (data not shown). In multivariable Cox
regression analysis, both recipient age and donor gender
retained statistically significant and independent associations
with PVAN risk, while variables potentially indicative of risk
for or occurrence of acute rejection before PVAN diagnosis
were, again, unrelated to PVAN risk (Table 3).
Figures 4 and 5 display the relationships between recipient
age at transplantation and donor gender with PVAN in the
form of Kaplan–Meier plots. Figure 4 demonstrates the
incidence of PVAN in recipients within five different age
cohorts based on age at the time of transplantation. As can be
seen, increasing age, particularly greater than 55 years, was
associated with increased cumulative incidence of PVAN. The
relative incidence of PVAN among recipient age cohorts was
calculated by Cox regression using the group of recipients
between 36 and 45 (n¼ 212) as a reference group. Compared
with this reference group, the incidence of PVAN was not
statistically different in recipients younger than 35 years
(n¼ 168) (hazard ratios (HR)¼ 1.1 (0.4–3.0), P¼NS) and in
recipients between 46 and 55 years (n¼ 239) (HR¼ 2.0
(0.87–4.6), P¼ 0.10). However, recipients aged between 56
and 65 years (n¼ 250) and older than 65 years (n¼ 157) had
a significantly higher incidence of PVAN compared with the
reference cohort (HR¼ 2.6 (1.2–5.8), P¼ 0.01 and HR¼ 2.7
(1.2–6.3), P¼ 0.02, respectively).
The incidence of PVAN was higher in recipients of female
kidneys (Figure 5, P¼ 0.016 log rank) and this relationship
was independent of the age of the recipient (Table 3).
Quantitatively, 26 of 464 (5%) recipients of male kidneys and
48 of 478 (9%) recipient of female kidneys developed PVAN
(P¼ 0.01, w2). This association was noted in living donor
recipients (4.8% vs 9.3%, P¼ 0.014) and a similar trend was
observed in recipients of deceased donor kidneys (6.3% vs
8.6%), although the latter did not reach statistical signifi-
cance. It should be noted that the sample size of deceased
donor recipients in this study is relatively small (n¼ 207 and
15 cases of PVAN) and that the number of female donors is
significantly lower among deceased donors (45%) than
among living donors (53%, P¼ 0.04).
DISCUSSION
The study reported here provides a detailed profile of factors
associated with increased risk of PVAN among patients
receiving KTx at our center during the past 5 years. The
results reveal both similarities to and differences from
existing reports.1–4,8–10,14,18–21 In support of the clinical
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Figure 2 | Histological characteristics of surveillance and
non-surveillance biopsies diagnostic of PVAN among the
study cohort. (a) Results for the sum of acute tubulointerstitial
abnormalities (Banff ’97 iþ t scores) and chronic tubulointerstitial
abnormalities (Banff ’97 ciþ ct scores) on PVAN diagnostic biopsies
are represented graphically for cases diagnosed by surveillance
biopsy (surv.) or by non-surveillance biopsy (non-surv). Results are
presented for iþ t and ciþ ct as the proportions of each subgroup
with no abnormality (combined score 0), mild abnormality (combined
score¼ 1 or 2), moderate abnormality (combined score¼ 3 or 4), or
severe abnormality (combined score 44). (b) Results for
Drachenberg grading (A, B, or C) of PVAN diagnostic biopsies are
represented graphically for cases diagnosed by surveillance biopsy
(surv.) or by non-surveillance biopsy (non-surv.). The P-values shown
are the result of Fisher exact tests of combined Banff ’97 score and
Drachenberg grade distributions between surv. vs non-surv.
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Figure 3 | Graft survival for KTx recipients diagnosed with PVAN
by surveillance biopsy and non-surveillance biopsy. Kaplan–Meier
curves representing the rates of death-censored renal allograft
survival (defined as ‘return to dialysis or re-transplantation’) from the
time of transplantation to 48 months post-KTx are shown for
recipients diagnosed with PVAN by surveillance biopsy (n¼ 40) or by
non-surveillance biopsy (n¼ 34). Po0.01 for surveillance vs
non-surveillance.
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relevance of the findings, we have had the opportunity to
follow a large cohort of recent recipients in which the
cumulative frequency of biopsy-proven PVAN was substantial
and occurred predominantly during the first and second
post-transplant years. Thus, the statistical analyses can be
considered robust and the results reflective of recent practice.
The broad use of surveillance biopsies among this cohort has
also, we believe, assured a low likelihood of missed cases or
misidentification of advanced cases as chronic allograft
nephropathy.21 Importantly, clinical and histological com-
parison of those cases diagnosed by surveillance and non-
surveillance biopsies clarify the fact that the former do not
represent a distinct group of patients or constitute incidental
detection of a disease process devoid of the inflammatory and
fibrotic features that characterize clinically evident PVAN.
Finally, the characteristics of our program during the period
of observation reflect some emerging trends in KTx clinical
practice including rising living donation rates, advancing
recipient age, development of antibody reduction/desensiti-
zation strategies, and the use of non-calcineurin inhibitor-
based immunosuppression.22–25 The analysis of demographic
and clinical indices from this cohort indicates, quite clearly,
that two baseline factors – older recipient age and female
donor gender – were associated with increased PVAN risk,
whereas, within the limits of the number of patients studied,
other candidate factors – most notably HLA matching,
immunosuppression choice, and rejection history – were not.
A variety of risk factors have been linked with PVAN
diagnosis and with BKV reactivation in clinical KTx centers
from North America, Europe, Australia, and
Asia.1,10,20,21,26–28 In common with the majority of existing
studies, we do not find compelling evidence that induction
therapy or individual oral immunosuppressive medications
increase the incidence of PVAN.1 It is noteworthy that we
Table 3 | Cox regression analysis of the association between development of PVAN during follow-up and three clinical
variables in patients receiving kidney transplants between January 2000 and June 2004
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Recipient agea 1.3 (1.2–1.4) 0.004 1.3 (1.2–1.4) 0.001
Donor female gender 1.8 (1.1–2.9) 0.01 1.8 (1.1–2.8) 0.02
Acute rejection episodeb 0.9 (0.4–1.6) NS 1.02 (0.54–1.9) NS
Induction therapyc 1.0 (0.65–1.5) NS 1.47 (0.9–2.42) NS
Maintenance immunosuppressiond 0.7 (0.38–1.15) NS 0.64 (0.37–1.1) NS
CI, confidence intervals.
aHazard ratios (HR) were calculated for every 10 years increase in age.
bEntered as number of rejection episodes that occurred during the first year and, in patients with PVAN, only those that occurred before the diagnosis of PVAN.
cThese analyses tested no induction vs thymoglobulin induction vs anti-CD25 induction therapies.
dThese analyses tested tacrolimus vs sirolimus vs cyclosporine for maintenance immunosuppression.
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Figure 4 | Risk of PVAN among five recipient age cohorts.
Kaplan–Meier plots of the cumulative incidence of PVAN in recipients
classified according to their age at the time of transplant as indicated
in the figure margin (log rank¼ 0.03). Comparisons among groups
are indicated in the results section of the manuscript.
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Figure 5 | The incidence of PVAN among recipients of female
donor compared to male donor kidneys. Kaplan–Meier curves are
shown of the cumulative occurrence of biopsy-proven PVAN among
patients receiving KTxs from female donors compared with male
donors during the first 48 months post-transplant. There was a
significantly higher incidence of PVAN among recipients of female
kidneys (log rank¼ 0.016).
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have had the opportunity to compare PVAN among patients
managed by tacrolimus- and sirolimus-based regimens of
similar immunosuppressive potency and have observed no
difference between the two groups.29 One notable limitation
of our study is the fact that the number of cases in our cohort
managed primarily with cyclosporine was likely too small to
compare confidently the PVAN incidence with that of
patients managed with tacrolimus or sirolimus. In contrast
to our observations here, it has been reported by others that
lower level of HLA matching and prior history of acute
rejection are associated with higher PVAN risk.1,9,10,20 These
discrepancies, which have been noted recently in a compre-
hensive review of existing literature by Hirsch et al.,1 may well
reflect center-specific differences in overall patient demo-
graphic and immunosuppression practice. They may also,
however, derive from low numbers of index cases among the
patients studied or from increased likelihood of graft biopsy
in recipients with a history of rejection. By examining PVAN
incidence among a large, non-selected cohort of patients
undergoing graft biopsy independently of acute complica-
tions we believe that such confounding factors have been
eliminated from consideration in this study. It should be
noted that the influence of ureteral stent placement, which
has been reported as a risk factor for BK viremia by Brennan
et al.13 in a prospective clinical study, could not be evaluated
here as the practice was all but universal during the study
period. Similarly, the predominance of Caucasian recipients
in our patient populations does not allow a rigorous
examination of the influence of race on BKV-associated
disease.
The independent effect of recipient age on PVAN
incidence among our patients is in agreement with Ramos
et al.,19,30 who have also described a large experience with
PVAN within a carefully characterized KTx practice. The
explanation for this association cannot be directly deter-
mined here but is in accordance with age-related declines in
antiviral cellular immunity31 and, more specifically, with
population-based studies that indicate a waning of anti-BKV
immunity with age.32 In addition, recipient age may impact
the overall immunosuppressive potency of antirejection
therapy – particularly of three-drug regimens.33 The sig-
nificance of confirming and extending this observation is
two-fold. In the first place, older recipient age, as a readily
identified factor before transplantation, may be used to focus
post-KTx screening protocols for BKV reactivation and to
modify immunosuppression dosing and target levels. In the
second place, it may explain, in part, the dramatic emergence
of PVAN during the past 5 years – a period in which the
number of KTx recipients aged 50 years or more has
increased by over 100% in the USA, whereas the number of
recipients aged less than 50 years has remained static (source:
www.UNOS.org). It should also be emphasized that, based
on the current study as well as existing reports, pediatric and
young adult KTx recipients clearly have more than a minimal
risk for developing PVAN.4,28 Furthermore, there may be
specific immunologic or non-immunologic risk factors that
are operative in younger recipients that are not evident in our
current analysis.
The higher incidence of PVAN among recipients of female
kidneys is surprising and less readily explained on the basis of
existing data. Although a type I statistical error cannot be
definitively ruled out, we are confident that the association of
female donor gender with increased PVAN risk has been a
real clinical phenomenon in our KTx practice during the
study period. Having been identified in univariate analysis as
one of only two variables to be statistically and independently
associated with PVAN risk, the association was confirmed in
multivariate analysis involving five variables with the level of
significance remaining undiminished. Furthermore, Kaplan–-
Meier analysis demonstrated a clear, persistent divergence in
incidence of PVAN among recipients of female compared
with male donor kidneys throughout the first 48 months
post-transplant. To our knowledge, donor gender has not
been examined previously in studies of PVAN risk factors.
Although focal positivity of human native kidneys and
urinary tract for BKV has been reported in autopsy
specimens, the numbers analyzed have been too low to
determine whether such foci are more common among
females.34,35 It is possible that reactivation of BKV during
pregnancy results in a greater burden of latent virus among
women who subsequently serve as kidney donors.36 Smaller
organ size could also constitute a risk factor for the disease
itself or for more frequent diagnostic sampling of the medulla
and corticomedullary junction during allograft biopsy. As
with recipient age, it should be emphasized that female donor
gender has become significantly more common in recent
years as a result of the rise in living donor relative to deceased
donor numbers.24 Indeed, the consistent ratio of males to
females among deceased kidney donors in the USA (1.49:1
between 1988 and 2005) is entirely reversed for living donors
(0.75:1) (Source: www.UNOS.org). An important implica-
tion of our study on the basis of these two modifiers is that
renal allografts at risk for PVAN will continue to increase in
number in the coming years.
Although not the primary focus of this study, our analyses
provide some additional insight regarding the spectrum of
histological changes associated with PVAN at the time of
diagnosis and its relationship to subsequent clinical course.
Perhaps predictably, we demonstrate here that diagnosis by
surveillance biopsy portends significantly lower risk for graft
loss in the short-to-mid term. Despite this, the initial active
histological features of the disease, whether evaluated by
elements of the Banff ’97 scoring system or by grading
according to the modified-Drachenberg system (which
includes grading of viral cytopathy),1 were not strikingly
different between the surveillance and non-surveillance
biopsy-diagnosed groups. This observation is in keeping
with the recent report of Gaber et al.11 involving a detailed
histological analysis and clinical outcome in 20 PVAN cases
diagnosed following decline in renal function. In contrast, the
study by Gaber et al.11,12 as well as our previous work
indicates that the presence of advanced fibrosis on the
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diagnostic biopsy (Drachenberg grade C) is associated with
subsequent loss of renal function regardless of viral clearance
on follow-up biopsy. It should be noted that, presumably
owing to predominantly early diagnosis of PVAN in this
cohort, grade C cases were absent from the surveillance
biopsy group and infrequent among those diagnosed by
clinically indicated biopsy. Although we cannot formally rule
out the possibility that surveillance biopsy-diagnosed cases
represent a truly distinct clinical entity, our experience to
date favors the conclusion that these cases represent the
subclinical phase of a disease process that is likely to progress
to irreversible graft fibrosis and functional loss if left
undiagnosed.
There are some specific limitations to this analysis that
should be acknowledged. Although surveillance biopsy
capture rates at 4, 12, and 24 months have been high and
in situ hybridization for BKV is performed on all graft
biopsies with cytopathy or abnormal cellular infiltrates, this
should not be considered to represent the results of a
screening program designed to diagnose or rule out PVAN in
all cases. This being said, our practice is to maintain close
laboratory follow-up indefinitely on all recipients and to
carry out allograft biopsy for all cases of graft functional
decline. Thus, it is unlikely that the analysis has been skewed
by missed cases of PVAN. A second limitation in identifying
risk factors relates to the lack of stratification for donor and
recipient BKV status before transplantation. On the basis of
well-documented rates of seropositivity,1,30 it could be
expected that 10%–20% of transplants involve BKV-negative
donor and recipient. Furthermore, recent studies indicate
that donor-derived virus is responsible for the large majority
of cases during the first post-transplant year – a fact that may
further limit the actual number of recipients at risk.35 We do
not believe, however, that the risk factors we have identified
are explicable by pretransplant serologic status of the donors
or recipients as anti-BKV antibodies have not been found to
be more prevalent among older individuals or among
females.32 Finally, the risk modifiers we observe are likely,
to some degree, to be specific to the patient population and
practice characteristics of our own center. It is certainly
possible that the prevalence of older, Caucasian recipients of
living donor kidneys among our cohort and the predominant
use of depleting induction therapy and tacrolimus/mycophe-
nolate mofetil-based immunosuppression with resulting low
overall rates of acute rejection have diminished the combined
impact of ‘immunological’ risk factors for PVAN in this study
and brought others to the fore. Thus, KTx programs with
predominantly younger recipients, with recipients of more
diverse ethnic backgrounds or with alternative antirejection
strategies (corticosteroid-free or rapidly weaned immuno-
suppression) may encounter PVAN risk factors that were not
operative among our cohort.9,10,18,19,36,37
In conclusion, our observation that older KTx recipients
(particularly those aged 56 years or greater at the time of
transplantation) and recipients of female kidneys are at
heightened risk for the potentially graft-destroying complica-
tion of PVAN provides an opportunity to target preventive
measures or intensified BKV screening strategies to specific
patient subgroups. With the increased utilization of BKV
screening and surveillance biopsies among KTx programs
worldwide, it will be possible to determine the degree to
which these disease modifiers operate within different
practice models.
MATERIALS AND METHODS
Patient population
The study included an analysis of 1027 adult KTx recipients (age
X18 years) transplanted at our institution between 1 January 2000
and 30 September 2004. Clinical and laboratory data were extracted
from electronic databases and from patient’s medical records
following IRB approval. The characteristics of this population are
displayed in Table 1. These KTx recipients included 50 blood group
(ABO) incompatible living donor grafts, 77 sensitized (‘positive
crossmatch’) living donor recipients, and 900 conventional deceased
or living donor grafts.
Intravenous induction was administered in the form of
antithymocyte globulin (Thymoglobulins 1.5 mg/kg – 4 to 8 doses
during the first 10 days post-KTx) in 83% of cases or anti-CD25
monoclonal antibody (Simulects 20 mg on days 0 and 4 post-KTx)
in 10% of cases. No induction therapy was used in 7% of cases.
Initial oral immunosuppression consisted of prednisone, tacrolimus,
and mycophenolate mofetil in 87% of patients. Cyclosporine and
sirolimus were used as alternatives to tacrolimus in 2 and 11%,
respectively. Combinations of tacrolimus or cyclosporine with
sirolimus were not employed as primary immunosuppression
during this time period. The dose of tacrolimus was adjusted to
achieve trough levels of 10–15 ng/ml during the first month; 8–12 ng/
ml during months 2 to 4, and 6–10 ng/ml thereafter. In patients
receiving sirolimus, the dose was adjusted to achieve trough levels of
15–20 ng/ml during the first 4 months post-KTx and 10–15 ng/ml
thereafter. In those receiving cyclosporine, the dose was adjusted to
achieve trough levels of 200–250 ng/ml during the first 4 months
post-KTx and 100–200 ng/ml thereafter. During the study period,
immunosuppression was not tailored for older recipients during the
early post-transplant months or at other times. Recipients of ABO
incompatible and positive cross-match grafts additionally received
one or more antibody-reducing therapies including plasmapheresis,
anti-CD20 monoclonal antibody, splenectomy, and high-dose
intravenous immunoglobulin as described elsewhere.38,39 For the
purposes of this study, acute rejection was defined as acute cellular
rejection (including borderline and all other Banff ’97 grades) or
acute humoral rejection present on a renal allograft biopsy
interpreted by a consultant renal pathologist. All such episodes
were treated by corticosteroid intravenous boluses and oral taper
with or without depleting antibody therapy regardless of whether
the diagnosis was made on clinically indicated or surveillance
biopsy.
Renal allografts biopsies and diagnosis of PVAN
Renal allograft biopsies were performed as part of a surveillance
protocol (surveillance biopsies) throughout the study period as well
as for diagnostic purposes in KTx recipients with unexplained
decline in graft function (non-surveillance biopsies). All recipients
were asked to provide consent for surveillance allograft biopsy
during transplantation surgery (‘time zero’) and at 4 and 12 months
post-KTx. Final capture rates for these surveillance biopsies were 95,
1308 Kidney International (2007) 71, 1302–1309
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75, and 65% for each of the three time points. Beginning in 2004,
recipients have been additionally asked to consent to surveillance
biopsy at 24 and 60 months post-KTx. All biopsies were interpreted
by consultant renal pathologists and consisted of serial sections
stained with hematoxylin and eosin, periodic acid-Schiff, methena-
mine silver, and Masson’s trichrome stains. In addition to narrative
reporting, each biopsy was scored for acute and chronic abnorm-
alities according to Banff ’97 criteria.37 In situ hybridization for BKV
DNA was performed on paraffin-embedded tissue sections as
previously described.12,15 A diagnosis of PVAN was confirmed for
any KTx recipient having a renal allograft biopsy report of
characteristic histological abnormalities (tubulointerstitial infiltrates
and/or epithelial cell cytopathic changes) with nuclear positivity of
multiple epithelial cells by BKV-specific in situ hybridization.
Data analysis
Data are expressed as means7s.d. throughout the paper. Means of
normally distributed data were compared by Student t-test. Data
that were not normally distributed were compared by non-
parametric tests. w2 and Fisher exact tests were used to compare
proportions. Assessment of variables associated with the diagnosis of
PVAN was performed by Cox regression and Kaplan–Meier analyses.
Comparison of death-censored graft survival for surveillance and
non-surveillance biopsy-diagnosed PVAN was carried out by
Kaplan–Meier analysis.
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